Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Elicio Therapeutics (ELTX) Total Current Liabilities (2020 - 2026)

Elicio Therapeutics filings provide 4 years of Total Current Liabilities readings, the most recent being $9.8 million for Q4 2023.

  • On a quarterly basis, Total Current Liabilities rose 42.04% to $9.8 million in Q4 2023 year-over-year; TTM through Dec 2023 was $9.8 million, a 42.04% increase, with the full-year FY2023 number at $9.8 million, up 42.04% from a year prior.
  • Total Current Liabilities hit $9.8 million in Q4 2023 for Elicio Therapeutics, down from $11.5 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $107.4 million in Q4 2020 to a low of $2.0 million in Q1 2023.
  • Median Total Current Liabilities over the past 4 years was $10.4 million (2022), compared with a mean of $18.3 million.
  • Biggest five-year swings in Total Current Liabilities: plummeted 89.49% in 2021 and later surged 42.04% in 2023.
  • Elicio Therapeutics' Total Current Liabilities stood at $107.4 million in 2020, then plummeted by 89.49% to $11.3 million in 2021, then plummeted by 39.2% to $6.9 million in 2022, then skyrocketed by 42.04% to $9.8 million in 2023.
  • The last three reported values for Total Current Liabilities were $9.8 million (Q4 2023), $11.5 million (Q3 2023), and $7.6 million (Q2 2023) per Business Quant data.